PD Hinduja Hospital, Khar, has introduced CAR-T cell therapy with ImmunoACT. NexCAR19 (Actalycabtagene autoleucel) is India’s first gene-modified cell treatment for patients aged 15 and above with relapsed or refractory B-cell lymphoma and B-acute lymphoblastic leukemia.
NexCAR19, developed by ImmunoACT with IIT-Bombay and Tata Memorial Centre, modifies T-cells into cancer fighters. This CAR-T cell therapy, autologous and targeting CD19 protein, benefits patients unresponsive to traditional therapies.
CAR-T therapy provides advantages with a single infusion treatment, improving patients’ quality of life at one-tenth the global cost.
Gautam Khanna, CEO of PD Hinduja Hospital, said, “We are among the first healthcare institutions in Mumbai to offer CAR-T cell therapy.”
Dr (Prof) Vijay Patil, Consultant, Medical Oncology at PD Hinduja Hospital, sees CAR-T as new therapies for resistant cancers. Dr Ashay Karpe, Consultant, Hemato-Oncology, anticipates the program providing hope for cancer patients.
Shirish Arya, Co-founder & Director of Business Development and Corporate Strategy, ImmunoAct explained the collaboration’s impact. Partnering with PD Hinduja Hospital aimed to broaden NexCAR19 accessibility, contributing to improved outcomes and patients’ quality of life, he said.
